Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy.
Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy.
复制标题
DOI：
10.3390/ijms23010350
复制
发表时间：
2021-12-29
影响因子：
5.6
通讯作者：
Li W
中科院分区：
文献类型：
--
作者：
He Y;Tian H;Dai C;Wen R;Li X;Webster KA;Li W
早产儿视网膜病变（ROP）是一种发生于早产儿的新生血管性视网膜疾病，是儿童失明的主要原因。目前，在美国还没有批准的用于ROP的药物疗法，突出了对治疗该疾病的新型治疗剂的迫切的未满足的临床需求。分泌颗粒蛋白III（Secretogranin III，Scg 3）是一种疾病选择性血管生成因子，Scg 3中和性单克隆抗体在小鼠模型中可减轻病理性视网膜新生血管形成。在这项研究中，我们通过实施组织学和功能分析来表征全长人源化抗Scg3抗体（hAb）改善氧诱导视网膜病变（OIR）小鼠（ROP的替代模型）中视网膜病理的功效和安全性。我们的结果表明，抗Scg3 hAb在治疗OIR小鼠的有效性和安全性方面优于血管内皮生长因子抑制剂aflibercept。我们的研究结果支持抗Scg3 hAb的开发用于临床应用。
The retinopathy of prematurity (ROP), a neovascular retinal disorder presenting in premature infants, is the leading causes of blindness in children. Currently, there is no approved drug therapy for ROP in the U.S., highlighting the urgent unmet clinical need for a novel therapeutic to treat the disease. Secretogranin III (Scg3) was recently identified as a disease-selective angiogenic factor, and Scg3-neutralizing monoclonal antibodies were reported to alleviate pathological retinal neovascularization in mouse models. In this study, we characterized the efficacy and safety of a full-length humanized anti-Scg3 antibody (hAb) to ameliorate retinal pathology in oxygen-induced retinopathy (OIR) mice, a surrogate model of ROP, by implementing histological and functional analyses. Our results demonstrate that the anti-Scg3 hAb outperforms the vascular endothelial growth factor inhibitor aflibercept in terms of efficacy and safety to treat OIR mice. Our findings support the development of anti-Scg3 hAb for clinical application.
登录
查看更多内容
影响因子：
3.7
作者：
Nakamura S;Imai S;Ogishima H;Tsuruma K;Shimazawa M;Hara H
通讯作者：
Hara H
影响因子：
0.8
作者：
Benchorin, Gillie;Calton, Melissa A.;Vollrath, Douglas
通讯作者：
Vollrath, Douglas
影响因子：
4.4
作者：
Lutty, Gerard A.;McLeod, D. Scott;Wiegand, Stanley J.
通讯作者：
Wiegand, Stanley J.
DOI：
10.1084/jem.20161802
发表时间：
2017-04-03
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
LeBlanc ME;Wang W;Chen X;Caberoy NB;Guo F;Shen C;Ji Y;Tian H;Wang H;Chen R;Li W
通讯作者：
Li W
影响因子：
168.9
作者：
Hellstrom, Ann;Smith, Lois E. H.;Dammann, Olaf
通讯作者：
Dammann, Olaf